CompletedPhase 2

A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

United States300 participantsStarted 2010-08

Plain-language summary

This study aims to evaluate the safety, tolerability and effectiveness of BTA798 on * shortening the length and reducing the symptoms of human rhinovirus infection (also known as the common cold), * controlling asthma symptoms, and * lowering the risk of asthma symptoms worsening in subjects with asthma.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male and female subjects aged 18-70 years * Diagnosis of asthma consistent with Global Initiative for Asthma (GINA) steps 1 to 3 * Presumptive human rhinovirus infection Exclusion Criteria: * Current severe asthma exacerbation * Severe asthma, GINA steps 4 or higher * Uncontrolled or clinically significant medical condition, disease or event which could impact subject safety and/or study evaluations and/or compliance to the protocol * Current smoker, ex-smoker of \<1 year, or history of smoking \>/=10 pack years.

What they're measuring

Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire

Timeframe: Days 2-4

Trial details

NCT IDNCT01175226

SponsorBiota Scientific Management Pty Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2012-03

Results submitted2017-03-17

View on ClinicalTrials.gov More Rhinovirus trials